(Q36509683)

14 August 2017

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma (English)

1 reference

metastatic renal cell carcinoma

14 August 2017

0 references

1 reference

angiogenesis inhibitor

1 reference

1 reference

1 reference

5

Steven A Rosenberg

1 reference

14 August 2017

Dina M Elaraj

1

1 reference

14 August 2017

Donald E White

2

1 reference

14 August 2017

Seth M Steinberg

3

1 reference

14 August 2017

Leah Haworth

4

1 reference

14 August 2017

James C Yang

6

1 reference

14 August 2017

1 July 2004

1 reference

14 August 2017

Journal of Immunotherapy

1 reference

14 August 2017

27

1 reference

14 August 2017

4

1 reference

14 August 2017

259-264

1 reference

Thalidomide for recurrent renal-cell cancer in a 40-year-old man.

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Antitumor activity of thalidomide in refractory multiple myeloma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Thalidomide is an inhibitor of angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Role of interferons in the therapy of metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

30 September 2017

Cancer statistics, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Mutations of the VHL tumour suppressor gene in renal carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

A phase II study of thalidomide in advanced metastatic renal cell carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Phase II trial of thalidomide in renal-cell carcinoma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Mathematical model to predict individual survival for patients with renal cell carcinoma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275325

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15235386

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15235386

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15235386

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/00002371-200407000-00001

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

15235386

1 reference